INDIVIDUAL VARIATION IN RENAL DOSIMETRY OF Lu-177 OCTREOTATE

被引：0
|
作者：
McKay, Erin [1 ]
机构：
[1] St George Hosp, Sydney, NSW, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2013年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [41] Dynamic Cell Dosimetry Model for in Vitro Cell Assays with 177Lu-DOTA Octreotate
    Konijnenberg, M. W.
    Verwijnen, S.
    de Jong, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S101 - S101
  • [42] Dynamic Tumour Dosimetry Model for Peptide Radionuclide Therapy with 177Lu-DOTA-Octreotate
    Konijnenberg, M. W.
    Bernard, B. F.
    De Jong, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S101 - S101
  • [43] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [44] High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-Octreotate in a rat tumor model.
    Erion, JL
    Bugaj, JE
    Schmidt, MA
    Wilhelm, RR
    Srinivasan, A
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 223P - 223P
  • [45] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [46] Comparative evaluation of carrier added and non carrier added Lu-177 for preparation of therapeutic doses of Lu-177 radiopharmaceuticals
    Bhusari, P.
    Shukla, J.
    Singh, H.
    Sood, A.
    Mittal, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S688 - S688
  • [47] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [48] Bone marrow dosimetry after [Lu-177-DOTA0, Tyr3]octreotate
    Forrer, Flavio
    Krenning, Eric
    Kooij, Peter
    Konijnenberg, Mark
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [49] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [50] Size matters: A saga of Lu-177 yield
    Vyas, Madhusudan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
12345